SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Hepatocellular Carcinoma: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Hepatocellular Carcinoma.

Related Posts

EC approves Pfizer’s Talzenna combo for prostate cancer...

Jan 9, 2024

STAT+: Q&A: Sen. Sanders on insulin costs and his commi...

May 9, 2023

Gliosarcoma drugs in development, 2023

Nov 30, 2023